Compare SERV & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SERV | MYGN |
|---|---|---|
| Founded | 2017 | 1991 |
| Country | United States | United States |
| Employees | 380 | 2700 |
| Industry | Industrial Specialties | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.8M | 372.1M |
| IPO Year | 2023 | 1996 |
| Metric | SERV | MYGN |
|---|---|---|
| Price | $4.37 | $3.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $17.67 | $7.64 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $207,545.00 | ★ $771,400,000.00 |
| Revenue This Year | $920.26 | $6.86 |
| Revenue Next Year | $184.90 | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 92.49 | 2.33 |
| 52 Week Low | $4.17 | $2.74 |
| 52 Week High | $18.64 | $8.59 |
| Indicator | SERV | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 60.67 |
| Support Level | $4.31 | $2.89 |
| Resistance Level | $5.88 | $5.42 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 37.20 | 86.49 |
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. The Segment derives revenue from (i) services via the Companies robot fleet, including delivery, branding and experiential services, (ii) access to software developed for the robot fleet, including certain autonomous capabilities, and (iii) access to data collected by the robot fleet, including navigation-related data. The majority of the revenue is derived from robot delivery services and food delivery platforms.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.